Privately-held company GAIA has had more than a front-row seat to observe the arrival of digital therapeutics and applications of AI in pharma over the past qua 4 June 2024
With a steady flow of oncology results emerging from the ongoing ASCO meeting, a company such as Pierre Fabre, which does not have major data to present, might 3 June 2024
Marc de Garidel, chief executive of French clinical-stage biotech Abivax (Nasdaq: ABVX), has good reason for his belief in the company’s pioneering lead asset, 13 May 2024
Privately-held Isotope Technologies Munich (ITM) is not just the radiopharmaceutical company that can do it all—from manufacturing and supplying medical radiois 26 April 2024
Staying true to her values is not a secondary consideration for Dr Dennise Broderick in her career and leadership of Galen, but rather is front and central to e 7 March 2024
Germany-based Vivoryon Therapeutics could well be on the path towards altering the course of Alzheimer’s disease (AD), with a PhII data readout coming up and a 9 February 2024
Last month, the European Commission (EC) approved Ebglyss (lebrikizumab) for the treatment of adult and adolescent patients with moderate-to-severe atopic derma 21 December 2023
US biotech Novavax has an advanced purchase agreement (APA) with the European Commission and an arrangement with the UK for the supply of the firm’s COVID-19 va 8 December 2023
Across pharma companies.teams attend so many congresses.meet with so many key opinion leaders (KOLs) and have such a plethora of data surrounding these activiti 7 November 2023
On Tuesday, US biotech company Novavax, which is advancing protein-based vaccines with its Matrix-M adjuvant, announced a timely update with its Nuvaxovid XBB.1 1 November 2023
Leading regulatory bodies around the world have various pathways in place to speed up the approval process for promising medicines that offer a solution to unme 6 October 2023
The past year has been one of ups and downs for Blueprint Medicines Corporation, a US precision medicines company developing therapies for people with cancer an 20 September 2023
US biotech Cytokinetics is seeking to develop medicines that treat cardiovascular and neuromuscular diseases of impaired muscle function. 15 August 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.